Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma

To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.

Trial Details

NCT ID
NCT06467097
Phase
PHASE3
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • SBRT(Stereotatic Body Radiation Therapy)
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patients with metastatic renal cell carcinoma classified within the ESTRO/EORTC classification system as having ≤ 5 metastases, ≤ 3 metastatic orga…
  • Patients aged 20 to 80 years.
  • Patients with individual metastases ≤ 5 cm in longest diameter.
  • Patients with primary tumors surgically removed or scheduled for surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →